Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current classification of anti-arrhythmia agents].

J Weirich1, W Wenzel

  • 1Physiologisches Institut der Universität, Freiburg.

Zeitschrift Fur Kardiologie
|May 16, 2000
PubMed
Summary

Antiarrhythmic drugs are classified by Vaughan Williams classes (I-IV) based on their effects on myocardial targets. Drug choice depends on electrophysiological effects and frequency dependence, crucial for managing arrhythmias and avoiding proarrhythmic risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuning Electronic and Structural Properties of Lead-Free Metal Halide Perovskites: A Comparative Study of 2D Ruddlesden-Popper and 3D Compositions.

Chemphyschem : a European journal of chemical physics and physical chemistry·2024
Same author

Unveiling oxygen vacancy impact on lizardite thermo and mechanical properties.

Scientific reports·2023
Same author

Revealing the impact of organic spacers and cavity cations on quasi-2D perovskites via computational simulations.

Scientific reports·2023
Same author

How cation nature controls the bandgap and bulk Rashba splitting of halide perovskites.

Journal of computational chemistry·2023
Same author

Determination of specific and non-specific protein-protein interactions for beta-lactoglobulin by analytical ultracentrifugation and membrane osmometry experiments.

Soft matter·2022
Same author

Hemispherical differences in the shape and topography of asteroid (101955) Bennu.

Science advances·2020

Area of Science:

  • Cardiology
  • Pharmacology
  • Electrophysiology

Background:

  • Antiarrhythmic drugs are classified into four Vaughan Williams classes (I-IV) based on their electrophysiological effects on the myocardium.
  • These classes target specific myocardial channels: sodium, potassium, and calcium, as well as beta-adrenergic receptors.
  • The "Sicilian Gambit" offers a more detailed classification based on drug targets.

Purpose of the Study:

  • To emphasize that selecting antiarrhythmic drugs requires understanding their electrophysiological effects.
  • To highlight the critical role of frequency dependence in determining antiarrhythmic and proarrhythmic properties.
  • To differentiate subclasses of Class I and Class III antiarrhythmics based on their specific mechanisms and rate-dependent behaviors.

Main Methods:

  • Analysis of the Vaughan Williams classification and the "Sicilian Gambit" approach.
  • Evaluation of the frequency dependence of electrophysiological effects for Class I (sodium-channel blockade) and Class III (potassium-channel blockade) antiarrhythmics.
  • Differentiation of Class III drugs based on their inhibition of specific potassium current components (IKr and IKs).

Main Results:

  • Class I drug's sodium-channel blockade is rate-dependent, with subclassification based on block-frequency relation.
  • Class III drugs inhibiting IKr show reverse rate dependence, potentially causing torsades de pointes at low heart rates.
  • Class III drugs inhibiting IKs are under investigation, potentially showing rate-independent effects but with uncertain proarrhythmic risk, as suggested by LQT1 syndrome.

Conclusions:

  • Appropriate antiarrhythmic drug selection hinges on understanding electrophysiological effects and rate dependence.
  • Understanding specific channel targets (IKr vs. IKs) is crucial for predicting drug behavior and potential proarrhythmic risks.
  • Further research is needed for Class III drugs targeting IKs to ascertain their safety profile, especially concerning congenital long QT syndrome.

Related Experiment Videos